Argus Downgrades Catalent to Sell From Buy

Catalent (CTLT) has an average hold rating and a price target range of $46 to $63.50, according to analysts polled by Capital IQ. Price: 55.42, Change: -0.19, Percent Change: -0.34

MT NewswiresMay 17 02:26

Unusual Options Activity: PBR, GME and Others Attract Market Bets, PBR V/OI Ratio Reaches 312.5

EST May 15th Afternoon Delivery - In the last two hours of trading, 5 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options trends

Futu NewsMay 16 01:30

Novo Nordisk will sell four types of Eurobonds to finance the acquisition of Catalent's plant

Gronghui, May 14 | People familiar with the matter revealed that on Tuesday, several banks will sell Euro-denominated bonds with 4 maturities on behalf of Novo Nordisk through Novo Nordisk's financial subsidiary in the Netherlands, with terms ranging from 2 to 10 years. Novo Nordisk issued bonds for the first time in more than two years to fund plans to increase production of its major drug. A Novo Nordisk spokesperson said the proceeds will be used to help the Danish pharmaceutical giant buy the Catalent plant for $11 billion. According to reports, the company is investing heavily to expand its production capacity, and announced plans to acquire three plants originally owned by Catalent earlier this year

Gelonghui FinanceMay 14 21:26

Update: Market Chatter: Novo Nordisk Taps Banks for Potential Bond Issue

(Updates to add Novo Nordisk's response) Novo Nordisk (NOVO-B.CO) hired banks for the potential issue of euro-nominated bonds to fund general corporate purposes, including funding its $16.5 billion ac

MT NewswiresMay 14 15:15

Form 144 | Catalent(CTLT.US) Insider Proposes to Sell 176.62K in Common Stocks

SEC FILLINGS DISCLOSED/ May 13, $Catalent(CTLT.US)$ Insider Crane Rosemary A intends to sell 3,167 shares of its common stock on May 13, with a total market value of approximately $176.62K. Crane Ro

Futu NewsMay 14 04:05

Market Chatter: Novo Nordisk Taps Banks for Potential Bond Issue

Novo Nordisk (NOVO-B.CO) hired banks for the potential issue of euro-nominated bonds to fund general corporate purposes, including funding its $16.5 billion acquisition of US-based Catalent. Bloomberg

MT NewswiresMay 13 23:44